Your browser doesn't support javascript.
loading
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Kohan, Donald E; Fioretto, Paola; Tang, Weihua; List, James F.
Affiliation
  • Kohan DE; Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
  • Fioretto P; Department of Medicine, University of Padua, Padua, Italy.
  • Tang W; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • List JF; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey, USA.
Kidney Int ; 85(4): 962-71, 2014 Apr.
Article in En | MEDLINE | ID: mdl-24067431
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Glucosides Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Kidney Int Year: 2014 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Glucosides Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Kidney Int Year: 2014 Document type: Article Affiliation country: United States Country of publication: United States